We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
The latest trading session saw Abbott (ABT - Free Report) ending at $113.19, denoting a +0.78% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.16%. Elsewhere, the Dow gained 0.86%, while the tech-heavy Nasdaq lost 0.38%.
The maker of infant formula, medical devices and drugs's shares have seen a decrease of 0.94% over the last month, surpassing the Medical sector's loss of 5.3% and the S&P 500's loss of 2.2%.
The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on January 22, 2025. On that day, Abbott is projected to report earnings of $1.34 per share, which would represent year-over-year growth of 12.61%. Meanwhile, our latest consensus estimate is calling for revenue of $11.02 billion, up 7.64% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.02% higher. Abbott is currently sporting a Zacks Rank of #2 (Buy).
With respect to valuation, Abbott is currently being traded at a Forward P/E ratio of 21.85. This indicates a premium in contrast to its industry's Forward P/E of 18.88.
One should further note that ABT currently holds a PEG ratio of 2.4. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 142, finds itself in the bottom 44% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
The latest trading session saw Abbott (ABT - Free Report) ending at $113.19, denoting a +0.78% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.16%. Elsewhere, the Dow gained 0.86%, while the tech-heavy Nasdaq lost 0.38%.
The maker of infant formula, medical devices and drugs's shares have seen a decrease of 0.94% over the last month, surpassing the Medical sector's loss of 5.3% and the S&P 500's loss of 2.2%.
The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on January 22, 2025. On that day, Abbott is projected to report earnings of $1.34 per share, which would represent year-over-year growth of 12.61%. Meanwhile, our latest consensus estimate is calling for revenue of $11.02 billion, up 7.64% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.02% higher. Abbott is currently sporting a Zacks Rank of #2 (Buy).
With respect to valuation, Abbott is currently being traded at a Forward P/E ratio of 21.85. This indicates a premium in contrast to its industry's Forward P/E of 18.88.
One should further note that ABT currently holds a PEG ratio of 2.4. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 142, finds itself in the bottom 44% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.